Malaria vaccine candidate: Design of a multivalent subunit α-helical coiled coil poly-epitope

Vaccine

Volumn 29, Issue 40, 2011, Pages 7090-7099

  Olugbile, Sope ^a,i   Villard, Viviane ^b   Bertholet, Sylvie ^c,j   Jafarshad, Ali ^d   Kulangara, Caroline ^e   Roussilhon, Christian ^d   Frank, Geraldine ^b   Agak, George W ^b   Felger, Ingrid ^e   Nebie, Issa ^f   Konate, Karidia ^g   Kajava, Andrey V ^g   Schuck, Peter ^h   Druilhe, Pierre ^d   Spertini, François ^a   Corradin, Giampietro ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^d INSTITUT PASTEUR   (France)

^e SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^f Burkina Faso   (Burkina Faso)

^g Centre National de la Recherche Scientifique   (France)

^h NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

ⁱ HOSPITAL OF SAINT RAPHAEL   (United States)

^j NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

more..

Author keywords

Antibodies; Long synthetic peptide; Malaria; Vaccine

Indexed keywords

ANTIGEN; EPITOPE; IMMUNOGLOBULIN; MALARIA VACCINE; POLY EPITOPE P181; POLY EPITOPE P27; POLY EPITOPE P77; POLY EPITOPE P90; POLYPEPTIDE; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CELL PROLIFERATION; CIRCULAR DICHROISM; CROSS REACTION; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IN VITRO STUDY; MALARIA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN SYNTHESIS; SENEGAL; SERUM; SUBUNIT ALPHA HELICAL COILED COIL; T LYMPHOCYTE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; EPITOPES; FOLLOW-UP STUDIES; HUMANS; IMMUNE SERA; LONGITUDINAL STUDIES; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED C3H; MICE, INBRED ICR; PEPTIDES; PLASMODIUM FALCIPARUM; PROTEIN STRUCTURE, SECONDARY; SENEGAL; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 80052306843     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.122     Document Type: Article

References (30)

1. Hay S.I., Okiro E.A., Gething P.W., Patil A.P., Tatem A.J., Guerra C.A., et al. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med 2010, 7(6):1000290.
2. O'Meara W.P., Mangeni J.N., Steketee R., Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis 2010, 10(8):545-555.
3. Gardner M.J., Hall N., Fung E., White O., Berriman M., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002, 419(6906):498-511.
4. Villard V., Agak G.W., Frank G., Jafarshad A., Servis K., Nebie I., et al. Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. PLoS One 2007, 2(7):645.
5. Harbury P.B., Zhang T., Kim P.S., Alber T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 1993, 262(5138):1401-1407.
6. Atherton E., Sheppard R.C. Solid phase synthesis; a practical approach 1989, IRL Press, Oxford University Press, Oxford.
7. Balbo A., Brown P.H., Braswell E.H., Schuck P. Measuring protein-protein interactions by equilibrium sedimentation. Curr Protoc Immunol 2007, [Chapter 18, unit 18, p. 8].
8. Balbo A., Zhao H., Brown P.H., Schuck P. Assembly, loading, and alignment of an analytical ultracentrifuge sample cell. J Vis Exp 2009, 33.
9. Brown P.H., Balbo A., Schuck P. Characterizing protein-protein interactions by sedimentation velocity analytical ultracentrifugation. Curr Protoc Immunol 2008, [Chapter 18, unit 18, p. 15].
10. Schuck P. 2010. http://sedfitsedphat.nibib.nih.gov/software/default.aspx.
11. Cohn E.J., Edsall J.T. Density and apparent specific volume of proteins. Proteins, amino acids and peptides 1943, 370-381. Van Nostrand-Reinhold, Princeton, NJ.
12. Lepori L., Mollica V. Volumetric properties of dilute aqueous-solutions of poly(ethylene glycols). J Polym Sci B 1978, 16(6):1123-1134.
13. Vistica J., Dam J., Balbo A., Yikilmaz E., Mariuzza R.A., Rouault T.A., et al. Sedimentation equilibrium analysis of protein interactions with global implicit mass conservation constraints and systematic noise decomposition. Anal Biochem 2004, 326(2):234-256.
14. Olugbile S., Kulangara C., Bang G., Bertholet S., Suzarte E., Villard V., et al. Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage associated Plasmodium falciparum protein PFF0165c. Infect Immun 2009, 77:5701-5709.
15. Anderson R.C., Fox C.B., Dutill T.S., Shaverdian N., Evers T., Poshusta G.R., et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces 2010, 75(1):123-132.
16. Baldwin S.L., Bertholet S., Kahn M., Zharkikh I., Ireton G., Vedvick T., et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009, 27(23):3063-3071.
17. Bouharoun-Tayoun H., Attanath P., Sabchareon A., Chongsuphajaisiddhi T., Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 1990, 172(6):1633-1641.
18. Jafarshad A., Dziegiel M.H., Lundquist R., Nielsen L.K., Singh S., Druilhe P. A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. J Immunol 2007, 178(5):3099-3106.
19. Rogier C., Trape J.F. Study of premunition development in holo- and meso-endemic malaria areas in Dielmo and Ndiop (Senegal): preliminary results, 1990-1994. Med Trop (Mars) 1995, 55(Suppl. 4):71-76.
20. Roussilhon C., Oeuvray C., Müller-Graf C., Tall A., Rogier C., Trape J.F. Long-term clinical protection from P. falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med 2007, 4(11):320.
21. Olugbile S., Habel C., Servis C., Spertini F., Verdini A., Corradin G. Malaria vaccines - the long synthetic peptide approach: technical and conceptual advancements. Curr Opin Mol Ther 2010, 12(1):64-76.
22. Agak G.W., Bejon P., Fegan G., Gicheru N., Villard V., Kajava A.V. Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya. Vaccine 2008, 26(16):1963-1971.
23. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17(2):189-194.
24. Kallinteris N.L., Lu X., Wu S., Hu H., Li Y., Gulfo J.V., et al. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine 2003, 21(27-30):4128-4132.
25. Kocken C.H., Hundt E., Knapp B., Brazel D., Enders B., Narum D.L., et al. Immunization of Aotus monkeys with recombinant Plasmodium falciparum hybrid proteins does not reproducibly result in protection from malaria infection. Infect Immun 1998, 66(1):373-375.
26. Linhart B., Hartl A., Jahn-Schmid B., Verdino P., Keller W., Krauth M.T., et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 2005, 115(5):1010-1016.
27. Naruse H., Ogasawara K., Takami K., Kajino K., Gotohda T., Itoh Y., et al. Analysis of epitopic residues introduced into the hybrid peptide vaccines prepared according to the cassette theory. Vaccine 1994, 12(9):776-782.
28. Sirima S.B., Tiono A.B., Ouédraogo A., Diarra A., Ouédraogo A.L., Yaro J.B., et al. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months old Burkinabe children. PLoS One 2009, 4(10):7549.
29. Mordmüller B., Szywon K., Greutelaers B., Esen M., Mewono L., Treut C., et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria exposed, adult individual from Lambarene, Gabon. Vaccine 2010, 28(41):6698-6703.
30. Kulangara C., Kajava A.V., Corradin G., Felger I. Sequence conservation in Plasmodium falciparum alpha helical coiled-coil domains proposed for vaccine development. PLoS One 2009, 4(5):5419.